10/501 700

2006. OMB 0651-0031 ENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A-PTO Application No. Not Yet Assigned Filing Date Herewith INFORMATION DISCLOSURE First Named Inventor Kappel STATEMENT BY APPLICANT Art Unit Not Yet Assigned Pohnert Examiner Name (Use as many sheets as necessary) Sheet 1 Attorney Docket No. 612,406-043

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Document No. Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/SP/	1.	WO 02/090512	11/2002	Genaissance Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	er Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bor magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published		T²	
/SP/	2.	DONG, et al., "BRAF Oncogenic Mutations Correlate with Progression Rather Than Initiation of Human Melanoma", CANCER RESEARCH 63(14): 3883-85 (July 15, 2003)		
/SP/-	3.	DATABASE EMBL, 'Online! 15 June 1992 (1992-06-15) SITHANANDAM et al., "Homo sapiens B-raf protein (BRAF) mRNA, complete cds", retrieved from EBI, Database accession no. M95712 abstract		
/SP/	4.	DAVIES et al., "Mutations of the BRAF Gene in Human Cancer," NATURE 417: 949-54 (June 27, 2002)		
/SP/	5.	URIBE P., WISTUBA I. and GONZALEZ S., "BRAF Mutation. A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin," AM. J. DERMATOPATHOL. 25(5): 365-70 (October 2003)		

Examiner Signature	/Steven Pohnert/ (06/03/2008)		
NB1:686485.1	·	Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents. the indication of the year of the reign of the Emporor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB-08a (08 03)